CheckMate-915 Trial Does Not Meet Co-Primary End Point of RFS for Melanoma

Source: cancer network, October 2020

Updated results from the randomized, phase 3 CheckMate-915 trial found that nivolumab (Opdivo) plus ipilimumab (Yervoy) did not result in a statistically significant improvement in recurrence-free survival (RFS) in the intention-to-treat population of participants, according to Bristol Myers Squibb, the developer of the agents.

The study is evaluating the nivolumab-ipilimumab combination versus nivolumab alone in patients who have had a complete surgical removal of stage IIIb/c/d or stave IV melanoma.

“We are proud of our legacy in melanoma with both [nivolumab] and [ipilimumab],” Sabine Maier, MD, vice president and head of Oncology Clinical Development at Bristol Myers Squibb, said in a press release.

READ THE ORIGINAL FULL ARTICLE